Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

BACKGROUND: In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added to chemotherapy. In Morocco, we conducted an observational study to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulaamane, Lamiaa, Boutayeb, Saber, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337253/
https://www.ncbi.nlm.nih.gov/pubmed/22439740
http://dx.doi.org/10.1186/1756-0500-5-162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337253/
https://www.ncbi.nlm.nih.gov/pubmed/22439740
http://dx.doi.org/10.1186/1756-0500-5-162

Ejemplares similares